Brünés, Nina
Lindstroem, Mette Bendtz
Ulrik, Charlotte Suppli
Andersen, Ove
Lisby, Marianne
Godtfredsen, Nina Skavlan
Hansen, Tina Leth
Pisinger, Charlotta
Graven, Vibeke
Marsaa, Kristoffer
Thomsen, Laura Hohwü
Funding for this research was provided by:
Copenhagen University
Article History
Received: 20 December 2023
Accepted: 22 February 2024
First Online: 5 March 2024
Declarations
:
: This study will be conducted in accordance with ethical principles derived from international guidelines including the Helsinki Declaration [CitationRef removed]. All participants will have to provide informed written consent for participation and publication of study results.The study protocol received approval from the Regional Ethics Committee (H-20031386, December 10, 2020) and is registered on ClinicalTrials.gov (reference NCT04754308, February 12, 2021). The collection and processing of data have been authorized by the Capital Region on behalf of the Danish Data Agency (P-2020-137).
: Not applicable.
: Kristoffer Marsaa reports personal fees for lectures from Astellas Pharma, GlaxoSmithKline, AstraZeneca, Novartis, Boehringer Ingelheim, Kyowa Kirin, Norgine, outside the submitted work.Charlotte Suppli Ulrik has received fees for lectures, participation in advisory boards etc. from AZ, GSK, Novartis, Sanofi, Chiesi, TEVA, Boehringer Ingelheim, Berlin Chemie, Pfizer, TFF pharmaceuticals and Orion Pharma outside the submitted work.